Hodgkin lymphoma, also known as Hodgkin's lymphoma or Hodgkin's disease, is a type of lymphoma, in which cancer originates from white blood cells called lymphocytes.
Biotherapy options have emerged for patients with B-lineage Non-Hodgkins Lymphoma (NHL). A series of novel mAbs with specificity for a variety of surface antigens are currently under evaluation. Rituximab used both for biotherapy of patients with B-lineage NHL who experience a recurrence of their disease after frontline therapy as well as for frontline treatment of B-lineage NHL patients who are at high risk to experience a recurrence after chemotherapy.Hodgkin Lymphoma (HL) shows a 3rd month anti-TNF therapy which needs to be modified and pursue immunosuppressive therapy with anti-TNF drugs, which were also used in the treatment of rheumatic diseases.
The top journals are peer reviewed scholarly journals. These provide high quality, meticulously reviewed and rapid publication, to cater the insistent need of scientific community. These journals are indexed with all their citations noted. The top open access journals are indexed in MEDLINE, PUBMED, SCOPUS, COPERNICUS, CAS, EBSCO and ISI.
Last date updated on September, 2014